Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: Different quasispecies?
Hepatitis B X gene
Hepatitis B virus RNA
Next-generation sequencing
Quasispecies
Quasispecies complexity
Quasispecies conservation
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Nov 2021
07 Nov 2021
Historique:
received:
08
07
2021
revised:
20
08
2021
accepted:
18
10
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Different forms of pregenomic and other hepatitis B virus (HBV) RNA have been detected in patients' sera. These circulating HBV-RNAs may be useful for monitoring covalently closed circular DNA activity, and predicting hepatitis B e-antigen seroconversion or viral rebound after nucleos(t)ide analog cessation. Data on serum HBV-RNA quasispecies, however, is scarce. It is therefore important to develop methodologies to thoroughly analyze this quasispecies, ensuring the elimination of any residual HBV-DNA. Studying circulating HBV-RNA quasispecies may facilitate achieving functional cure of HBV infection. To establish a next-generation sequencing (NGS) methodology for analyzing serum HBV-RNA and comparing it with DNA quasispecies. Thirteen untreated chronic hepatitis B patients, showing different HBV-genotypes and degrees of severity of liver disease were enrolled in the study and a serum sample with HBV-DNA > 5 Log No HBV-DNA contamination was detected in cDNA samples from HBV-RNA quasispecies. HBV quasispecies complexity showed heterogeneous behavior among patients. The Rare Haplotype Load at 1% was greater in DNA than in RNA quasispecies, with no statistically significant differences ( Our methodology allowed analyzing HBV-RNA quasispecies complexity and conservation without interference from HBV-DNA. Thanks to this, we have been able to compare both quasispecies in the present study.
Sections du résumé
BACKGROUND
BACKGROUND
Different forms of pregenomic and other hepatitis B virus (HBV) RNA have been detected in patients' sera. These circulating HBV-RNAs may be useful for monitoring covalently closed circular DNA activity, and predicting hepatitis B e-antigen seroconversion or viral rebound after nucleos(t)ide analog cessation. Data on serum HBV-RNA quasispecies, however, is scarce. It is therefore important to develop methodologies to thoroughly analyze this quasispecies, ensuring the elimination of any residual HBV-DNA. Studying circulating HBV-RNA quasispecies may facilitate achieving functional cure of HBV infection.
AIM
OBJECTIVE
To establish a next-generation sequencing (NGS) methodology for analyzing serum HBV-RNA and comparing it with DNA quasispecies.
METHODS
METHODS
Thirteen untreated chronic hepatitis B patients, showing different HBV-genotypes and degrees of severity of liver disease were enrolled in the study and a serum sample with HBV-DNA > 5 Log
RESULTS
RESULTS
No HBV-DNA contamination was detected in cDNA samples from HBV-RNA quasispecies. HBV quasispecies complexity showed heterogeneous behavior among patients. The Rare Haplotype Load at 1% was greater in DNA than in RNA quasispecies, with no statistically significant differences (
CONCLUSION
CONCLUSIONS
Our methodology allowed analyzing HBV-RNA quasispecies complexity and conservation without interference from HBV-DNA. Thanks to this, we have been able to compare both quasispecies in the present study.
Identifiants
pubmed: 34887634
doi: 10.3748/wjg.v27.i41.7144
pmc: PMC8613647
doi:
Substances chimiques
Antiviral Agents
0
Cell-Free Nucleic Acids
0
DNA, Viral
0
RNA
63231-63-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7144-7158Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Authors have no conflict of interest for this manuscript.
Références
J Hepatol. 2020 Jul;73(1):40-51
pubmed: 32087349
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32554476
Virus Res. 2017 Jul 15;239:115-125
pubmed: 28040474
World J Gastroenterol. 2019 Apr 7;25(13):1566-1579
pubmed: 30983817
J Hepatol. 2017 Sep 21;:
pubmed: 28870671
J Infect Dis. 2016 Jan 15;213(2):224-32
pubmed: 26216905
Nat Rev Gastroenterol Hepatol. 2020 Oct;17(10):618-634
pubmed: 32467580
J Hepatol. 2020 Mar;72(3):539-557
pubmed: 31730789
Nat Methods. 2018 Jan 3;15(1):8-9
pubmed: 29298290
BMC Gastroenterol. 2019 Apr 16;19(1):53
pubmed: 30991954
World J Gastroenterol. 2018 May 21;24(19):2095-2107
pubmed: 29785078
Virol Sin. 2019 Feb;34(1):42-49
pubmed: 30610573
Hepatology. 2004 Oct;40(4):855-64
pubmed: 15382118
PLoS One. 2018 Oct 3;13(10):e0204877
pubmed: 30281674
Antiviral Res. 2018 Oct;158:34-44
pubmed: 30059722
Infect Drug Resist. 2020 Jun 22;13:1881-1888
pubmed: 32606837
Sci Rep. 2021 Feb 18;11(1):4215
pubmed: 33603102
Eur J Biochem. 2003 Jul;270(14):2929-36
pubmed: 12846825
Hepatology. 2015 Jan;61(1):66-76
pubmed: 25132147
J Hepatol. 2016 Oct;65(4):700-710
pubmed: 27245431
J Hepatol. 2017 Oct;67(4):847-861
pubmed: 28778687
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Hepatology. 2019 Apr;69(4):1816-1827
pubmed: 30362148